SITE005-0001

SITE005 (FRA) › SITE005-0001

SITE005-0001

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE005 (FRA) · Dr. Muller
consented 2025-08-18

enrolled

AEs

5

Serious

0

Dropout signal

–

Adverse events

5

Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-10-29 (study day 244); relationship: not assessed

mild assessed

Grade 2 Nausea — outcome: UNKNOWN; onset 2022-08-17 (study day 171); relationship: NOT RELATED

moderate assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-05-15 (study day 77); relationship: not assessed

mild assessed

Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-04-07 (study day 39); relationship: not assessed

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-04-04 (study day 36); relationship: NOT RELATED

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.